Mass spectrometry
MS sequence maps of mRNA using partial RNase T1
Open access · cc by · source: Europe PMC
A short digest with bead-bound RNase T1 plus tandem MS covers more than 80% of long mRNA sequences in one run, beating complete T1 maps.
Study at a glance
- Design
- Other — Immobilized partial RNase T1 digestion with IP-RP LC–MS/MS for large RNA/mRNA mapping
- N
- Analytical method on 20–40 μg RNA inputs — no biological cohort N
- Population
- Large RNAs and therapeutic mRNA samples
- Outcome
- Sequence coverage from partial vs complete T1 mapping (>80% from one partial digest)
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
>80% sequence coverage of large RNAs/mRNA therapeutics from a single partial digest, better than conventional complete T1 digestion, with few matches to random control sequences. The same workflow can flag modified mRNA and impurities.
Methodology
Authors digested 20–40 μg RNA with immobilized RNase T1 (2–15 min, 37 or 60 °C), separated oligoribonucleotides by IP-RP LC, identified fragments with high-res MS/MS and automated software, and compared complete vs partial T1 maps including spike mRNA.
Limitations
A fully validated GMP QC kit with inter-lab precision is still future work; coverage is not 100%, and complete T1 maps remain complementary.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
This library holds 5 empirical chemistry papers on mass spectrometry with isolated findings, rates or spectra rather than reviews.
Evidence for the claim as stated.
A short digest with bead-bound RNase T1 plus tandem MS covers more than 80% of long mRNA sequences in one run, beating complete T1 maps.
Evidence for the claim as stated.
Partial RNase T1 digestion plus ion-pair reversed-phase LC–MS/MS can map large RNAs better than a complete digest. From 20–40 μg RNA (2–15 min, 37 or 60 °C), a single partial digest gives >80% sequence coverage of large RNAs/mRNA therapeutics, with few matches to random control sequences. Coverage is not 100%; complete T1 maps remain complementary, and a GMP QC kit is future work.
Evidence for the claim as stated.
HPLC as a sequence map, as an activity assay, and as a preparative cut are different jobs. Partial T1 LC–MS aims at >80% mRNA coverage; PDMS–HPLC-fluorescence reports PAH activity (LoQ 0.1–2.5 μM); peptide HPLC isolates 12% yield A19-CF₃ insulin. A student who says 'we ran HPLC' has not said whether the chromatogram is identity, quantity, or a bucket to collect a product.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
HPLC as a sequence map, as an activity assay, and as a preparative cut are different jobs. Partial T1 LC–MS aims at >80% mRNA coverage; PDMS–HPLC-fluorescence reports PAH activity (LoQ 0.1–2.5 μM); peptide HPLC isolates 12% yield A19-CF₃ insulin. A student who says 'we ran HPLC' has not said whether the chromatogram is identity, quantity, or a bucket to collect a product.
Related papers in this topic
Same topic cluster — not a recommendation engine.